As filed with the Securities and Exchange Commission on April 29, 2013
Registration No. 333 -
UNITED STATES
SECURITIES AND EXCHANGE COMMISSION
WASHINGTON, D.C. 20549
FORM S-8
REGISTRATION STATEMENT
UNDER
THE SECURITIES ACT OF 1933
BG MEDICINE, INC.
(Exact Name of Registrant as Specified in Its Charter)
Delaware | 04-3506204 | |
(State or Other Jurisdiction of Incorporation or Organization) |
(I.R.S. Employer Identification No.) | |
610 Lincoln Street North, Waltham, Massachusetts | 02451 | |
(Address of Principal Executive Offices) | (Zip Code) |
BG MEDICINE, INC. 2010 EMPLOYEE, DIRECTOR AND CONSULTANT STOCK PLAN
BG MEDICINE, INC. 2010 EMPLOYEE STOCK PURCHASE PLAN
(Full Titles of the Plans)
Eric Bouvier
President and Chief Executive Officer
BG Medicine, Inc.
610 Lincoln Street North
Waltham, Massachusetts 02451
(781) 890-1199
(Name, Address and Telephone Number, Including Area Code, of Agent for Service)
Copies to:
William T. Whelan, Esq.
Linda K. Rockett, Esq.
Mintz, Levin, Cohn, Ferris, Glovsky and Popeo, P.C.
One Financial Center
Boston, Massachusetts 02111
(617) 542-6000
Facsimile: (617) 542-2241
Indicate by check mark whether the registrant is a large accelerated filer, an accelerated filer, a non-accelerated filer, or a smaller reporting company. See the definitions of large accelerated filer, accelerated filer and smaller reporting company in Rule 12b-2 of the Exchange Act.
Large accelerated filer | ¨ | Accelerated filer | x | |||
Non-accelerated filer | ¨ (Do not check if a smaller reporting company) | Smaller reporting company | ¨ |
CALCULATION OF REGISTRATION FEE
| ||||||||
Title of Securities to be Registered |
Amount to be Registered(1) |
Proposed Maximum Offering Price Per Share(2) |
Proposed Maximum Offering Price(2) |
Amount of Registration Fee | ||||
Common Stock, par value $0.001 per share |
494,990 shares | $1.72 | $851,382.80 | $116.13 | ||||
| ||||||||
|
(1) | The number of shares of common stock, par value $0.001 per share (Common Stock), of BG Medicine, Inc. (the Registrant) stated above consists of (a) 449,991 additional shares of Common Stock reserved under the BG Medicine, Inc. 2010 Employee, Director and Consultant Stock Plan (the 2010 Stock Plan) as a result of the automatic increase in shares reserved thereunder on January 1, 2013 pursuant to the terms of the 2010 Stock Plan; and (b) 44,999 additional shares of Common Stock reserved under the BG Medicine, Inc. 2010 Employee Stock Purchase Plan (the 2010 ESPP and together with the 2010 Stock Plan, the Plans) as a result of the automatic increase in shares reserved thereunder on January 1, 2013 pursuant to the terms of the 2010 ESPP. In addition, pursuant to Rule 416 under the Securities Act of 1933, as amended (the Securities Act), this Registration Statement covers, in addition to the number of shares stated above, an indeterminate number of shares which may be subject to grant or otherwise issuable after the operation of certain anti-dilution and other provisions of the Plans. |
(2) | Estimated solely for the purpose of calculating the amount of the registration fee pursuant to Rule 457(h) and Rule 457(c) promulgated under the Securities Act. The offering price per share and the aggregate offering price for the additional shares reserved for future grant or issuance under the 2010 Stock Plan and additional shares reserved for future issuance under the 2010 ESPP, are based on the average ($1.7197) of the high and the low price of Registrants Common Stock as reported on The NASDAQ Global Market as of a date (April 24, 2013) within five business days prior to filing this Registration Statement. |
This Registration Statement registers additional securities of the same class as other securities for which the registration statement filed on Form S-8 (SEC File No. 333-172208) of the Registrant is effective. The information contained in the Registrants registration statement on Form S-8 (SEC File No. 333-172208) is hereby incorporated by reference pursuant to General Instruction E.
PART II
Item 8. | Exhibits. |
The Index of Exhibits immediately following the signatures to this Registration Statement is incorporated herein by reference.
2
SIGNATURES
Pursuant to the requirements of the Securities Act of 1933, the Registrant certifies that it has reasonable grounds to believe that it meets all of the requirements for filing on Form S-8 and has duly caused this Registration Statement to be signed on its behalf by the undersigned, thereunto duly authorized, in the City of Waltham, Massachusetts on April 29, 2013.
BG MEDICINE, INC. | ||
By | /s/ Eric Bouvier | |
Eric Bouvier | ||
President and Chief Executive Officer |
Each person whose signature appears below constitutes and appoints Eric Bouvier and Charles H. Abdalian, Jr., and each of them singly, his true and lawful attorneys-in-fact and agents, with full power of substitution and resubstitution in each of them singly, for him and in his name, place and stead, and in any and all capacities, to sign any and all amendments (including post-effective amendments) to this Registration Statement on Form S-8 of BG Medicine, Inc., and to file the same, with all exhibits thereto and other documents in connection therewith, with the Securities and Exchange Commission, granting to the attorneys-in-fact and agents, and each of them, full power and authority to do and perform each and every act and thing requisite or necessary to be done in or about the premises, as full to all intents and purposes as he might or could do in person, hereby ratifying and confirming all that the attorneys-in-fact and agents or any of each of them or their substitute may lawfully do or cause to be done by virtue hereof.
Pursuant to the requirements of the Securities Act of 1933, this Registration Statement has been signed by the following persons in the capacities and on the dates indicated.
Signatures |
Title |
Date | ||||
By: | /s/ Eric Bouvier |
President and Chief Executive Officer (principal executive officer) and Director |
April 29, 2013 | |||
Eric Bouvier | ||||||
By: | /s/ Charles H. Abdalian, Jr. |
Executive Vice President, Chief Financial Officer and Treasurer (principal financial officer and principal accounting officer) |
April 29, 2013 | |||
Charles H. Abdalian, Jr. |
||||||
By: | /s/ Noubar B. Afeyan, Ph.D. |
Director | April 29, 2013 | |||
Noubar B. Afeyan, Ph.D. |
||||||
By: | /s/ Harrison Bains |
Director | April 29, 2013 | |||
Harrison M. Bains | ||||||
By: | /s/ Stéphane Bancel |
Executive Chairman of the Board of Directors |
April 29, 2013 | |||
Stéphane Bancel | ||||||
By: | /s/ Timothy Harris, Ph.D., D.Sc. |
Director | April 29, 2013 | |||
Timothy Harris, Ph.D., D.Sc. | ||||||
By: | /s/ Stelios Papadopoulos, Ph.D. |
Director | April 29, 2013 | |||
Stelios Papadopoulos, Ph.D. | ||||||
By: | /s/ Brian Posner |
Director | April 29, 2013 | |||
Brian Posner |
INDEX OF EXHIBITS
Exhibit |
Description | |
5.1 | Opinion of Mintz, Levin, Cohn, Ferris, Glovsky and Popeo, P.C. as to the legality of shares being registered. | |
23.1 | Consent of Mintz, Levin, Cohn, Ferris, Glovsky and Popeo, P.C. (included in opinion of counsel filed as Exhibit 5.1). | |
23.2 | Consent of Deloitte & Touche LLP. | |
24.1 | Power of Attorney to file future amendments (set forth on the signature page of this Registration Statement). |